Table 3 Delphi Study Participant Demographics
| Â | Round 1 | Round 2 | Round 3 | |||
|---|---|---|---|---|---|---|
5-point n = 101 | 9-point n = 104 | 5-point n = 76 | 9-point n = 71 | 5-point n = 69 | 9-point n = 63 | |
Stakeholder Group n (%) | ||||||
 Clinician | 43 (43%) | 48 (46%) | 30 (39%) | 29 (41%) | 27 (39%) | 25 (40%) |
 Clinician Researcher | 23 (23%) | 15 (14%) | 19 (25%) | 14 (20%) | 19 (28%) | 14 (22%) |
 Patient | 20 (20%) | 22 (21%) | 14 (18%) | 12 (17%) | 10 (14%) | 8 (13%) |
 Researcher | 10 (10%) | 13 (13%) | 10 (13%) | 11 (15%) | 10 (14%) | 11 (17%) |
 Service Provider/Policy Maker | 5 (5%) | 6 (6%) | 3 (4%) | 5 (7%) | 3 (4%) | 5 (8%) |
Gender n (%) | ||||||
 Female | 73 (72%) | 86 (83%) | 57 (75%) | 57 (80%) | 51 (74%) | 50 (79%) |
 Male | 27 (27%) | 18 (17%) | 19 (25%) | 14 (25%) | 18 (26%) | 13 (21%) |
 Prefer not to say | 1 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Age n (%) | ||||||
 18–24 | 2 (2%) | 1 (1%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 25–34 | 19 (19%) | 22 (21%) | 16 (21%) | 12 (17%) | 13 (19%) | 9 (14%) |
 35–44 | 34 (34%) | 40 (38%) | 23 (30%) | 28 39%) | 20 (29%) | 24 (38%) |
 45–54 | 24 (24%) | 20 (19%) | 19 (25%) | 16 (23%) | 18 (26%) | 15 (24%) |
 55–64 | 18 (18% | 15 (14%) | 15 (20%) | 11 (15%) | 15 (22%) | 11 (17%) |
 65+ | 4 (4%) | 6 (6%) | 2 (3%) | 4 (6%) | 2 (3%) | 4 (6%) |
Country n (%) | ||||||
 Argentina | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Australia | 4 (4%) | 4 (4%) | 3 (4%) | 3 (4%) | 3 (4%) | 3 (5%) |
 Austria | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 Belgium | 3 (3%) | 1 (1%) | 3 (4%) | 1 (1%) | 3 (4%) | 1 (2%) |
 Brazil | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 Canada | 6 (6%) | 11 (11%) | 4 (5%) | 9 (13%) | 4 (6%) | 9 (14%) |
 Colombia | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 Cook Islands | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Croatia | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Denmark | 1 (1%) | 2 (2%) | 1 (1%) | 2 (3%) | 1 (1%) | 2 (3%) |
 Egypt | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Finland | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 Germany | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 Iceland | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Iran | 0 (0%) | 2 (2%) | 0 (0%) | 2 (3%) | 0 (0%) | 2 (3%) |
 Ireland | 26 (26%) | 19 (18%) | 18 (24%) | 13 (18%) | 14 (20%) | 10 (16%) |
 Israel | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) |
 Malaysia | 4 (4%) | 0 (0%) | 2 (3%) | 0 (0%) | 2 (3%) | 0 (0%) |
 Mexico | 0 (0%) | 3 (3%) | 0 (0%) | 3 (4%) | 0 (0%) | 2 (3%) |
 Nepal | 2 (2%) | 0 (0%) | 2 (3%) | 0 (0%) | 2 (3%) | 0 (0%) |
 Netherlands | 3 (3%) | 1 (1%) | 3 (4%) | 1 (1%) | 3 (4%) | 1 (2%) |
 New Zealand | 1 (1%) | 2 (2%) | 1 (1%) | 1 (1%) | 1 (1%) | 1 (2%) |
 Norway | 7 (7%) | 7 (7%) | 7 (9%) | 4 (6%) | 7 (10%) | 4 (6%) |
 Philippines | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Poland | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) |
 Portugal | 1 (1%) | 2 (2%) | 1 (1%) | 1 (1%) | 1 (1%) | 1 (2%) |
 South Africa | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) |
 Sweden | 11 (11%) | 15 (14%) | 9 (12%) | 9 (13%) | 9 (13%) | 9 (14%) |
 Switzerland | 1 (1%) | 3 (3%) | 1 (1%) | 3 (4%) | 0 (0%) | 3 (5%) |
 UK | 11 (11%) | 17 (16%) | 8 (11%) | 9 (13%) | 7 (10%) | 5 (8%) |
 USA | 11 (11%) | 9 (9%) | 7 (9%) | 7 (10%) | 6 (9%) | 7 (11%) |
 Zimbabwe | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) |